Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | GALR3 | O60755 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | MYC | P01106 | 1/20 | 0.36 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.36 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3489434 | 0.83 | ALDH1A1 (0.64) | ALDH1A1MEN1KMT2ANCEH1CYP1A2 | |
| SCHEMBL29696047 | 0.82 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2ATDP1NCEH1 | |
| SCHEMBL156978 | 0.82 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2ATDP1NCEH1 | |
| SCHEMBL2706078 | 0.81 | PKM (0.44) | ALDH1A1MEN1KMT2ATDP1HPGD | |
| SCHEMBL28132 | 0.81 | KDM4E (0.54) | ALDH1A1MEN1KMT2ATDP1NCEH1 | |
| SCHEMBL10909 | 0.81 | ALDH1A1 (0.45) | ALDH1A1MEN1KMT2ATDP1NCEH1 | |
| SCHEMBL153277 | 0.81 | ALDH1A1 (0.71) | ALDH1A1MEN1KMT2ATDP1CYP1A2 | |
| SCHEMBL6270450 | 0.81 | ALDH1A1 (0.50) | ALDH1A1MEN1KMT2ATDP1CYP1A2 | |
| SCHEMBL149589 | 0.79 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2ATDP1NCEH1 | |
| SCHEMBL1349358 | 0.79 | MEN1 (0.45) | ALDH1A1MEN1KMT2ATDP1NCEH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3251679-B1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-12-16 | — | — | EP | disclosed |
| EP-2896397-B2 | Novel compounds having inhibitory activity against sodium-dependant glucose transporter | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-10-07 | — | — | EP | disclosed |
| EP-1651658-B2 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-08-12 | — | — | EP | disclosed |
| US-20180282363-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-10-04 | — | — | US | disclosed |
| EP-3251679-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER | Mitsubishi Tanabe Pharma Corporation (JP) | 2017-12-06 | — | — | EP | disclosed |
| EP-2896397-B1 | Novel compounds having inhibitory activity against sodium-dependant glucose transporter | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-09-06 | — | — | EP | disclosed |
| US-20160108078-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-04-21 | — | — | US | disclosed |
| EP-2896397-A1 | Novel compounds having inhibitory activity against sodium-dependant glucose transporter | Mitsubishi Tanabe Pharma Corporation (JP) | 2015-07-22 | — | — | EP | disclosed |
| EP-2514756-B1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-20140296506-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-10-02 | — | — | US | disclosed |
| EP-2514756-A1 | Novel compounds having inhibitory activity against sodium-dependant glucose transporter | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-10-24 | — | — | EP | disclosed |
| US-20120258913-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-10-11 | — | — | US | disclosed |
| US-8222219-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-07-17 | — | — | US | disclosed |
| US-8202984-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20120058941-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-08 | — | — | US | disclosed |
| US-7943788-B2 | Including the antidiabetic, antiobesity sodium glucose transport inhibitor Canagliflozin (1-( beta -D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene) | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-17 | — | — | US | disclosed |
| US-20110105424-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-05 | — | — | US | disclosed |
| EP-1651658-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER | TANABE SEIYAKU CO., LTD. (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-20050233988-A1 | Novel compounds | TANABE SEIYAKU CO., LTD. (JP) | 2005-10-20 | — | — | US | disclosed |
| WO-2005012326-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER | TANABE SEIYAKU CO., LTD. (JP) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058941-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | ALDH1A1 873/4885MEN1 1939/4885KMT2A 1170/4885 |
| US-20050233988-A1 | Novel compounds | CYP1B1, CYP4B1, CYP2B6 | ALDH1A1 831/4885MEN1 539/4885KMT2A 1509/4885 |
| US-20110105424-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | ALDH1A1 873/4885MEN1 1939/4885KMT2A 1170/4885 |
| US-20120258913-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | ALDH1A1 873/4885MEN1 1939/4885KMT2A 1170/4885 |
| US-20180282363-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | ALDH1A1 873/4885MEN1 1939/4885KMT2A 1170/4885 |
| US-20160108078-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | ALDH1A1 873/4885MEN1 1939/4885KMT2A 1170/4885 |
| US-20140296506-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | ALDH1A1 873/4885MEN1 1939/4885KMT2A 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.